Two Directors at Ra Pharmaceuticals Inc sold/sold after exercising options 12,883 shares at between 44.250USD and 45.165USD. The significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced financial results for the first quarter ended March 31, 2018 and provided an update on recent corporate and clinical developments. “We continue to make important progress in advancing our lead clinical candidate RA101495 SC in multiple, complement-mediated indications,” said Doug Treco, PhD, President and Chief Executive Officer of Ra Pharma. “While first generation treatments may address the basic mechanism of these diseases, the chall...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ra Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for the treatment of complement-mediated diseases, today announced that Doug Treco, Ph.D., President and Chief Executive Officer, will present at the Deutsche Bank 43rd Annual Health Care Conference on Tuesday, May 8, 2018 at 10:00 a.m. E.T. The conference is being held at the InterContinental Boston. A live webcast of the presentation can be ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced that the design of its Phase 2 clinical trial of RA101495 SC as a treatment for generalized myasthenia gravis (gMG) will be presented in an oral platform presentation at the 70th Annual American Academy of Neurology (AAN), taking place April 21-27, 2018 in Los Angeles. “Despite current treatments, patients with gMG suffer from the progressive and debilitating burden of complement-mediated neuromuscular damage,” said James F. Howard, MD,...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ra Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for the treatment of complement-mediated diseases, today announced the appointment of John C. King as Chief Commercial Officer, effective April 16, 2018. Mr. King brings to Ra Pharma more than 20 years of senior, global, commercial leadership experience within the biotechnology rare disease space, most recently with Alexion Pharmaceuticals. “H...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ra Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage biopharmaceutical company focused on the development of next-generation therapeutics for the treatment of complement-mediated diseases, today announced financial results for the fourth quarter and year ended December 31, 2017 and provided an update on recent corporate and clinical developments. “We made tremendous progress in 2017, advancing the development of our lead candidate, RA101495, a convenient, subcutaneous (SC), ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ra Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for the treatment of complement-mediated diseases, today announced that Doug Treco, Ph.D., President and Chief Executive Officer, will present at the Cowen and Company 38th Annual Health Care Conference on Wednesday, March 14, 2018 at 8:40 a.m. E.T. The conference is being held at the Boston Marriott Copley Place. A live webcast of the presentation c...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ra Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for the treatment of complement-mediated diseases, today announced that the design of its Phase 2 clinical trial of RA101495 SC for the treatment of generalized myasthenia gravis (gMG) will be presented in an oral platform presentation at the 70th Annual American Academy of Neurology (AAN) Meeting, taking place April 21-27, 2018 in Los Angeles. The stu...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ra Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for the treatment of complement-mediated diseases, today joins forces with 30 million health care advocates around the world for the 11th annual Rare Disease Day®. Rare Disease Day, which is always the last day of February, is an annual awareness day dedicated to elevating public understanding of rare diseases and calling attention to the special challenges p...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.